Licensing status

Publication and contact information


Brain cancer

H3 histone
family 3A
(H3.3A; H3F3A); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC); checkpoint
kinase 1
(Chk1); aurora kinase A
(AURKA; Aurora-A)

Cell culture studies suggest inhibiting Chk1 or AURKA may help treat pediatric and young adult patients with H3F3A-driven glioblastoma. In a glioblastoma cell line with G34-mutant H3F3A, MYCN was identified as the most highly overexpressed gene, and Chk1 and AURKA were identified as regulators of cell proliferation. In the same cell line, an AURKA inhibitor dose-dependently decreased MYCN levels and cell viability compared with no treatment. Next steps include testing AURKA and Chk1 inhibitors in a larger number of glioblastoma cell lines and building in vivo models to test the effects of the inhibitors in orthotopic brain tumors.
At least eight companies have AURKA inhibitors in preclinical to Phase III testing in various cancers.
At least six companies have Chk1 inhibitors in preclinical to Phase II trials in various cancer indications.

SciBX 6(18); doi:10.1038/scibx.2013.433
Published online May 9, 2013

Unpatented; licensing status not applicable

Bjerke, L. et al. Cancer Discov.; published online March 28, 2013;
Contact: Chris Jones, The Institute of Cancer Research, Surrey, U.K.